Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Total Liabilities of $153.0 million for Q1 2026, up 170.77% year-over-year from $56.5 million in Q1 2025, and down 13.68% quarter-over-quarter from $177.3 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Total Liabilities history runs 14 years deep, the most recent figure standing at $153.0 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 170.77% year-over-year to $153.0 million; the TTM figure through Mar 2026 stood at $153.0 million (up 170.77% YoY), while the FY2025 annual figure was $177.3 million, up 150.48% from the prior year.
- Total Liabilities for Q1 2026 stood at $153.0 million, down from $177.3 million in the prior quarter.
- The five-year high for Total Liabilities was $177.3 million in Q4 2025, with the low at $16.5 million in Q1 2022.
- The 5-year median for Total Liabilities is $48.4 million (2023), against an average of $61.7 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities dropped 1.85% in 2022, then jumped 170.77% in 2026.
- Viridian Therapeutics, Inc.\DE's Total Liabilities stood at $40.0 million in 2022, then increased by 20.92% to $48.4 million in 2023, then soared by 46.2% to $70.8 million in 2024, then soared by 150.48% to $177.3 million in 2025, then fell by 13.68% to $153.0 million in 2026.
- Business Quant data shows VRDN's Total Liabilities at $153.0 million in Q1 2026, $177.3 million in Q4 2025, and $74.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 435.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 435.14 Mn |
| Mar 31, 2026 | 153.01 Mn |
| Dec 31, 2025 | 177.25 Mn |
| Sep 30, 2025 | 74.17 Mn |
| Jun 30, 2025 | 67.16 Mn |
| Mar 31, 2025 | 56.51 Mn |
| Dec 31, 2024 | 70.76 Mn |
| Sep 30, 2024 | 64.40 Mn |
| Jun 30, 2024 | 56.33 Mn |
| Mar 31, 2024 | 47.85 Mn |
| Dec 31, 2023 | 48.40 Mn |
| Sep 30, 2023 | 45.18 Mn |
| Jun 30, 2023 | 35.61 Mn |
| Mar 31, 2023 | 36.09 Mn |
| Dec 31, 2022 | 40.03 Mn |
| Sep 30, 2022 | 31.57 Mn |
| Jun 30, 2022 | 27.92 Mn |
| Mar 31, 2022 | 16.52 Mn |
| Dec 31, 2021 | 15.99 Mn |
| Sep 30, 2021 | 16.61 Mn |